{"id":"kw-2246","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OX40 is an inducible T-cell co-stimulatory molecule that plays a key role in T-cell proliferation and survival. By blocking OX40 signaling, KW-2246 enhances T-cell mediated immune responses against cancer cells. This approach aims to overcome immune tolerance and improve anti-tumor efficacy, potentially as monotherapy or in combination with other immunotherapies.","oneSentence":"KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:11.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT00684632","phase":"PHASE3","title":"A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2008-03","conditions":"Pain, Cancer","enrollment":51},{"nctId":"NCT00683995","phase":"PHASE3","title":"A Phase III Clinical Study of KW-2246","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2008-03","conditions":"Pain, Cancer","enrollment":43},{"nctId":"NCT01326689","phase":"PHASE3","title":"A Comparative Study of KW-2246","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2011-03","conditions":"Cancer Related Pain (Breakthrough Pain)","enrollment":42},{"nctId":"NCT00355628","phase":"PHASE2","title":"Clinical Study of KW-2246 in Patients With Cancer Pain","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-07","conditions":"Pain, Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KW-2246","genericName":"KW-2246","companyName":"Kyowa Kirin Co., Ltd.","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KW-2246 is a small molecule used in clinical trials for the treatment of pain, cancer, and breakthrough pain in cancer patients. It has been studied in a Phase III clinical trial as a potential treatment for breakthrough pain in cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}